Tetra Noble launches new research program to treat canine carcinoma

LONDON, June 30, 2022 /PRNewswire/ — Tetra Noble Ltd, a UK-based pharmaceutical cannabis company, with planned GACP/EU-GMP production sites located in Portugal and South Africa. For the founders, Sam Gaffariand Liam’s Swamp, it’s not about trying to profit from a growing industry. Both were first to adapt to the market and have extensive experience in the pharmaceutical cannabis space and believe they are uniquely placed to disrupt the market in the UK and the global medical cannabis market.

Soheil (Sam) Ghaffari comes from a unique background in technology, finance and pharmaceutical cannabis. He is a geneticist and agronomist working with cannabis for 16 years, creating terrific genetics and has won numerous international awards for his genetics and research into cannabis strains and new natural cannabinoids. Sam has developed a proven track record in designing and implementing new medical/pharmaceutical cannabis projects, having successfully implemented it for various businesses in the UK as well as parts of Africa. Sam is also CEO and founder of Tetra Global Ltd, the first company to export medical cannabis genetics outside of the UK. Sam was a guest of honor at the United Nations General Assembly in 2019. Sam was a founding member of his last three cannabis companies, two of which progressed to a public listing while the third was acquired by the largest cannabis company in the world (Curaleaf).

Its co-founder, Liam’s Swampcomes from a successful experience in private equity based in the City of London, raising capital for private companies operating in new and emerging markets, primarily private medical cannabis companies. Since then, Liam has focused entirely on the operational and commercial aspects of the medical cannabis industry, playing an instrumental role in the commercial success of several medical cannabis projects in various countries. Since 2020, Liam has entered into several exclusive sales agreements with some of the largest importers and exporters of medicinal cannabis in the world, introducing over 10 tons of exports to date and generating millions of dollars in sales revenue. In 2021, Liam led the first licensed export of cannabis genetics from the UK to South Africa authorized for use in the production of an active pharmaceutical ingredient for medical use.

“We are pleased to announce that we have now reached the final stage of due diligence to launch our new research program which is investigating how cannabinoids can help treat carcinoma in dogs,” said Soheil Ghaffari (Sam) the CEO of Tetra Noble. With the recent appointment of Massimo Bresciani as Director of Research and Acting COO, after 15 years at GSK (GlaxoSmithKline plc) taking on several research programs through licensing and in the market.

Tetra Noble Ltd appears to be well positioned to be a market disruptor in the pharma cannabis space and is reminiscent of the early stages of GW Pharma but in a much more sophisticated and evolved market, giving it all the ingredients to succeed.

Contact:
Soheil Ghaffari
CEO
press@tetra-noble.com
+44 (0)3330 112983

Irene B. Bowles